Zydus Cadila begins human trials of its potential Covid-19 vaccine ZyCoV-D
Red Book
Red Book

Pre-cum-Mains GS Foundation Program for UPSC 2026 | Starting from 5th Dec. 2024 Click Here for more information

News: India has started the clinical trials of Covid-19 vaccine – ZyCoV-D.

Facts:

  • ZyCoV-D: It is a plasmid DNA vaccine designed and developed by Zydus, a pharmaceutical company.
  • The vaccine comes under the Vaccine Discovery Programme supported by the Department of Biotechnology under the National Biopharma Mission.

Additional Facts:

  • National Biopharma Mission(NBM): It is an Academia-Industry Collaborative Mission for Accelerating Discovery Research to Early Development for Biopharmaceuticals. 
  • Launched Year: It was launched in 2017 at a total cost of Rs 1500 crore and is 50% co-funded by World Bank loan.
  • Objective: To enable and nurture an ecosystem for preparing India’s technological development capabilities in biopharmaceuticals including vaccines, medical devices and diagnostics to a level that will be globally competitive over the next decade.
  • Implementation: Biotechnology Industry Research Assistance Council (BIRAC).
  • Innovate in India(i3) Programme: Under this Mission, the Government has launched Innovate in India(i3) programme to create an enabling ecosystem to promote entrepreneurship and indigenous manufacturing in the biopharma sector.

Discover more from Free UPSC IAS Preparation For Aspirants

Subscribe to get the latest posts sent to your email.

Print Friendly and PDF
Blog
Academy
Community